| scholarly article | Q13442814 |
| P2093 | author name string | John H Griffin | |
| Laurent O Mosnier | |||
| P2860 | cites work | Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide | Q43727878 |
| Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. | Q53320452 | ||
| Plasmin Desensitization of the PAR1 Thrombin Receptor: Kinetics, Sites of Truncation, and Implications for Thrombolytic Therapy† | Q58011108 | ||
| Immunoblotting studies of the molecular forms of protein C in plasma | Q67985678 | ||
| The endothelial cell protein C receptor. Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors | Q71144269 | ||
| The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis | Q73479520 | ||
| The endothelial cell protein C receptor | Q73818060 | ||
| Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective | Q24293646 | ||
| Activation of endothelial cell protease activated receptor 1 by the protein C pathway | Q24299215 | ||
| Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex | Q27622194 | ||
| The crystal structure of the endothelial protein C receptor and a bound phospholipid | Q27639046 | ||
| One single mRNA encodes the centrosomal protein CCD41 and the endothelial cell protein C receptor (EPCR) | Q28145805 | ||
| Molecular cloning and expression of murine and bovine endothelial cell protein C/activated protein C receptor (EPCR). The structural and functional conservation in human, bovine, and murine EPCR | Q28511217 | ||
| Efficacy and safety of recombinant human activated protein C for severe sepsis | Q29547839 | ||
| Thrombin signalling and protease-activated receptors | Q29619601 | ||
| Regulation of blood coagulation | Q33857528 | ||
| Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial | Q34518326 | ||
| Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke | Q34747354 | ||
| Protein C pathway in sepsis | Q35055016 | ||
| The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways | Q36371054 | ||
| YOPRO-1 permits cytofluorometric analysis of programmed cell death (apoptosis) without interfering with cell viability. | Q36681975 | ||
| The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. | Q37331775 | ||
| Permanent cell line expressing human factor VIII-related antigen established by hybridization | Q37615209 | ||
| Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner | Q40866653 | ||
| Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va | Q41142483 | ||
| Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis | Q43559207 | ||
| P433 | issue | Pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| drotrecogin alfa | Q412888 | ||
| P1104 | number of pages | 6 | |
| P304 | page(s) | 65-70 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Biochemical Journal | Q864221 |
| P1476 | title | Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor | |
| P478 | volume | 373 |
| Q38985138 | 2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C. |
| Q45821702 | A phosphoramidon-sensitive metalloprotease induces apoptosis of human endothelial cells by Group B Streptococcus |
| Q47846697 | Activated Protein C Attenuates Severe Inflammation by Targeting VLA-3high Neutrophil Subpopulation in Mice. |
| Q34488999 | Activated protein C N-linked glycans modulate cytoprotective signaling function on endothelial cells. |
| Q33846825 | Activated protein C action in inflammation |
| Q33798916 | Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact |
| Q33615455 | Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction |
| Q34390672 | Activated protein C has a protective effect against myocardial I/R injury by improvement of endothelial function and activation of AKT1. |
| Q37241529 | Activated protein C in sepsis: the promise of nonanticoagulant activated protein C. |
| Q38089190 | Activated protein C in the treatment of acute lung injury and acute respiratory distress syndrome |
| Q36012106 | Activated protein C induces endoplasmic reticulum stress and attenuates lipopolysaccharide-induced apoptosis mediated by glycogen synthase kinase-3β. |
| Q48384211 | Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage |
| Q28587775 | Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3 |
| Q33749766 | Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1. |
| Q37342603 | Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. |
| Q36997361 | Activated protein C promotes neuroprotection: mechanisms and translation to the clinic |
| Q40056621 | Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis |
| Q39063446 | Activated protein C protects vascular endothelial cells from apoptosis in malaria and in sepsis |
| Q45012436 | Activated protein C stimulates proliferation, migration and wound closure, inhibits apoptosis and upregulates MMP-2 activity in cultured human keratinocytes. |
| Q88984497 | Activated protein C, protease activated receptor 1, and neuroprotection |
| Q36478416 | Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin |
| Q26830499 | Activated protein C: A regulator of human skin epidermal keratinocyte function |
| Q35583397 | Activated protein C: biased for translation. |
| Q46461044 | Activation of protease-activated receptor-1 triggers astrogliosis after brain injury. |
| Q42751548 | Adjunct therapy for sepsis: how early? |
| Q52431401 | An ADAM-10 dependent EPCR shedding links meningococcal interaction with endothelial cells to purpura fulminans. |
| Q36195195 | An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. |
| Q36753466 | Apolipoprotein E Receptor 2 Mediates Activated Protein C-Induced Endothelial Akt Activation and Endothelial Barrier Stabilization |
| Q51076108 | Astragaloside IV inhibits PMA-induced EPCR shedding through MAPKs and PKC pathway. |
| Q92999563 | Baicalin Protects against Thrombin-Induced Cell Injury in Human Umbilical Vein Endothelial Cells |
| Q37159069 | Caveolae are required for protease-selective signaling by protease-activated receptor-1. |
| Q36349735 | Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma |
| Q47260653 | Coordinated responses of natural anticoagulants to allogeneic stem cell transplantation and acute GVHD - A longitudinal study. |
| Q36379329 | Cytoprotective protein C pathways and implications for stroke and neurological disorders |
| Q37214257 | Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. |
| Q43186023 | Distinct functions of activated protein C differentially attenuate acute kidney injury. |
| Q36607385 | Drotrecogin alfa (activated) in the treatment of severe sepsis |
| Q36981698 | Drotrecogin alpha (activated): the treatment for severe sepsis? |
| Q90221196 | EPCR promotes MGC803 human gastric cancer cell tumor angiogenesis in vitro through activating ERK1/2 and AKT in a PAR1-dependent manner |
| Q36842724 | Effects of anticoagulant strategies on activation of inflammation and coagulation |
| Q39173889 | Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor |
| Q36228995 | Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. |
| Q40178873 | Engineering a disulfide bond to stabilize the calcium-binding loop of activated protein C eliminates its anticoagulant but not its protective signaling properties |
| Q43244056 | Extracellular histone release in response to traumatic injury: implications for a compensatory role of activated protein C. |
| Q28578891 | FoxA2 involvement in suppression of protein C, an outcome predictor in experimental sepsis |
| Q40404028 | Global analysis of endothelial cell line proliferation patterns based on nutrient-depletion models: implications for a standardization of cell proliferation assays |
| Q37354434 | Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies |
| Q34579752 | Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. |
| Q36921588 | Heterozygous congenital Factor VII deficiency with the 9729del4 mutation, associated with severe spontaneous intracranial bleeding in an adolescent male |
| Q35457562 | Human thrombomodulin knock-in mice reveal differential effects of human thrombomodulin on thrombosis and atherosclerosis |
| Q37237490 | Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant |
| Q40117579 | Identification of a specific exosite on activated protein C for interaction with protease-activated receptor 1. |
| Q30434767 | Immune mechanisms and novel pharmacological therapies of acute kidney injury |
| Q35125057 | In vitro functional testing of endothelial progenitor cells that overexpress thrombomodulin |
| Q33919295 | Inhaled activated protein C protects mice from ventilator-induced lung injury |
| Q37408325 | Intrapleural Adenoviral-mediated Endothelial Cell Protein C Receptor Gene Transfer Suppresses the Progression of Malignant Pleural Mesothelioma in a Mouse Model |
| Q37112875 | Microparticle-associated endothelial protein C receptor and the induction of cytoprotective and anti-inflammatory effects |
| Q42692755 | Multifunctional specificity of the protein C/activated protein C Gla domain. |
| Q37217154 | Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity |
| Q36259602 | New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). |
| Q37065714 | Novel mechanisms for activated protein C cytoprotective activities involving noncanonical activation of protease-activated receptor 3. |
| Q47855675 | PAR1 Biased Signaling is Required for Activated Protein C In Vivo Benefits in Sepsis and Stroke |
| Q46022355 | PAR1 cleavage and signaling in response to activated protein C and thrombin. |
| Q35197451 | Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar |
| Q30425669 | Pathogenesis of acute kidney injury: foundation for clinical practice |
| Q41911467 | Plasminogen inhibits TNFalpha-induced apoptosis in monocytes |
| Q43667908 | Platelet factor 4 impairs the anticoagulant activity of activated protein C. |
| Q36319554 | Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke |
| Q43782027 | Prognostic value of platelet-derived growth factor in patients with severe sepsis |
| Q24314863 | Progress in the understanding of the protein C anticoagulant pathway |
| Q37186180 | Protease-activated receptor 1-dependent neuronal damage involves NMDA receptor function |
| Q36166264 | Protease-activated receptor-1 cleaved at R46 mediates cytoprotective effects. |
| Q64105617 | Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases |
| Q40339371 | Protease-activated receptors-1 and -2 can mediate endothelial barrier protection: role in factor Xa signaling |
| Q26999113 | Protein C anticoagulant and cytoprotective pathways |
| Q37913122 | Protein C anticoagulant system--anti-inflammatory effects |
| Q35669786 | Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells |
| Q37082968 | Recombinant human activated protein C: current insights into its mechanism of action |
| Q35839848 | Regulation of macrophage procoagulant responses by the tissue factor cytoplasmic domain in endotoxemia. |
| Q34746617 | Renal and urinary levels of endothelial protein C receptor correlate with acute renal allograft rejection |
| Q33370039 | Roles of protease-activated receptors in a mouse model of endotoxemia |
| Q48342249 | Selenium rescues orbital fibroblasts from cell death induced by hydrogen peroxide: another molecular basis for the effects of selenium in graves' orbitopathy. |
| Q36995847 | Sepsis: a clinical update. |
| Q33591571 | Single nucleotide variants in the protein C pathway and mortality in dialysis patients |
| Q37217113 | Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity |
| Q36070512 | The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis |
| Q37942050 | The endothelial cell protein C receptor: cell surface conductor of cytoprotective coagulation factor signaling. |
| Q36360425 | The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells |
| Q91999243 | The parmodulin NRD-21 is an allosteric inhibitor of PAR1 Gq signaling with improved anti-inflammatory activity and stability |
| Q37561507 | The protein C pathway and pathologic processes |
| Q38021497 | The protein C pathway in intestinal barrier function: challenging the hemostasis paradigm |
| Q36438845 | The safety profile of drotrecogin alfa (activated). |
| Q52610170 | The thermolysin-like metalloproteinase and virulence factor LasB from pathogenic Pseudomonas aeruginosa induces anoikis of human vascular cells. |
| Q33678549 | Thrombin and activated protein C inhibit the expression of secretory group IIA phospholipase A(2) in the TNF-alpha-activated endothelial cells by EPCR and PAR-1 dependent mechanisms |
| Q33222063 | Tick saliva is a potent inhibitor of endothelial cell proliferation and angiogenesis |
| Q36744024 | Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa |
| Q34999169 | Upregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitis |
Search more.